Mayo Clinic Collaborates with SHL Telemedicine using SmartHeart™ Technology 12 lead ECG

Study intends to evaluate the use of home telemonitoring SmartHeart technology to decrease hospital visits and lower healthcare utilization costs. Tel Aviv / Zurich / Newton MA, 14 October 2020 – Mayo Clinic and SHL Telemedicine Ltd., today announced a collaboration to evaluate the incidence of emergency department visits, rehospitalizations and MACE (major adverse cardiovascular events), and cost–effectiveness over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG, the golden standard ECG for diagnosing heart attack. For more information Click here